Health Care • Biotechnology: Pharmaceutical Preparations
$1.33 ▼ -0.16
(-10.74%)
MKT CAP: $67.2M • VOL: 376.4K
52W L $1 52W H $3
RNXT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.1M | $43.0K | $0 |
| YoY Revenue Growth % | +2511.6% | — | — |
| Gross Profit | $796.0K | $43.0K | — |
| Gross Margin % | 70.9% | 98.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$12.5M | -$11.0M | -$11.4M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$11.2M | -$8.8M | -$10.2M |
| EBITDA (Normalized) | -$12.5M | -$11.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$11.0M | -$9.1M | -$10.3M |
| Capital Expenditures (CapEx) | $2.0K | $12.0K | — |
| Free Cash Flow (FCF) | -$11.0M | -$9.1M | -$10.3M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $7.0M | $7.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $5.4M | $4.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RNXT.